Skip to content
10-Q

Quarterly Report

Amneal Pharmaceuticals, Inc. AMRX

0001723128-26-000020

← back to feed
Filed
May 7, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · Apr 30, 2026 319.02M sh
Shares Diluted Q1 2026 · Mar 31, 2026 328.93M sh
Shares Diluted Q1 2026 · Mar 31, 2025 323.96M sh
Capex Q1 2026 · Mar 31, 2026 $8.18M
Capex Q1 2026 · Mar 31, 2025 $13.16M
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$26.74M
Operating Cash Flow Q1 2026 · Mar 31, 2025 $7.41M
Long Term Debt Q1 2026 · Mar 31, 2026 $2.57B
Long Term Debt Q1 2026 · Dec 31, 2025 $2.57B
Short Term Debt Q1 2026 · Mar 31, 2026 $6.2M
Short Term Debt Q1 2026 · Dec 31, 2025 $6.76M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $197.66M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $282.03M
Cash And Equivalents Q1 2026 · Mar 31, 2025 $59.19M
Stockholders Equity Q1 2026 · Mar 31, 2026 −$45.41M
Stockholders Equity Q1 2026 · Dec 31, 2025 −$70.79M
Current Liabilities Q1 2026 · Mar 31, 2026 $728.05M
Current Liabilities Q1 2026 · Dec 31, 2025 $881.63M
Current Assets Q1 2026 · Mar 31, 2026 $1.8B
Current Assets Q1 2026 · Dec 31, 2025 $1.91B
Total Assets Q1 2026 · Mar 31, 2026 $3.54B
Total Assets Q1 2026 · Dec 31, 2025 $3.68B
Eps Diluted Q1 2026 · Mar 31, 2026 $0.19
Eps Diluted Q1 2026 · Mar 31, 2025 $0.04
Eps Basic Q1 2026 · Mar 31, 2026 $0.20
Eps Basic Q1 2026 · Mar 31, 2025 $0.04
Sga Expense Q1 2026 · Mar 31, 2026 $138.86M
Sga Expense Q1 2026 · Mar 31, 2025 $118.29M
Rd Expense Q1 2026 · Mar 31, 2026 $38.38M
Rd Expense Q1 2026 · Mar 31, 2025 $40.04M
Net Income Q1 2026 · Mar 31, 2026 $62.26M
Net Income Q1 2026 · Mar 31, 2025 $12.2M
Operating Income Q1 2026 · Mar 31, 2026 $141.77M
Operating Income Q1 2026 · Mar 31, 2025 $100.35M
Gross Profit Q1 2026 · Mar 31, 2026 $320.11M
Gross Profit Q1 2026 · Mar 31, 2025 $255.89M
Cost Of Revenue Q1 2026 · Mar 31, 2026 $402.41M
Cost Of Revenue Q1 2026 · Mar 31, 2025 $439.53M
Revenue Q1 2026 · Mar 31, 2026 $722.52M
Revenue Q1 2026 · Mar 31, 2025 $695.42M